Data sharing partnership will expand chemical coverage space and improve model performance in support of new approach methodologies to ensure product safety
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced it has entered a new collaboration with a large agrochemicals company to extend the industry’s top-rated machine learning model for the prediction of ionization constants (pKa) in the ADMET Predictor® platform.
The team at Simulations Plus will use the partner company's proprietary measurements, drawn from its vast internal databases, to build and refine its predictive model that can accurately predict pKa values of various chemical compounds. Additionally, Simulations Plus will create and evaluate new algorithms and techniques to further enhance the predictive capabilities of the model.
Dr. Robert Fraczkiewicz, Research Fellow and Project Lead, said: “The importance of this new partnership cannot be overstated, as the outcomes will help improve the accuracy of predictions and greatly expand the chemical coverage space that can be accurately analyzed. In turn, this should help drive next generation safety assessment strategies using ADMET Predictor and GastroPlus®. This is especially important for the chemicals, cosmetics, and consumer goods industries, as global regulations have restricted the use of animal testing. Data sharing collaborations between organizations are becoming increasingly valuable in the advancement of machine learning and its applications, and our team is dedicated to providing our partners with reliable, secure, and efficient models and workflows that help them succeed.”
“The utilization of ADMET Predictor within ‘non-pharmaceutical’ markets has been growing, and this collaboration with one of the most innovative companies in this space should help accelerate its adoption,” added Dr. Eric Jamois, Senior Director for Key Accounts and Strategic Alliances. “By combining our advanced property prediction technologies with the data and expertise of our partner, we can achieve more accurate and reliable results. This will help to ensure new chemical products are developed with the highest level of safety. Improvements made to ADMET Predictor will be made available for all clients to apply to their research activities. Simulations Plus continues to invite future collaborations which benefit all user groups and, most importantly, the global communities that we serve.”
About Simulations Plus
Serving clients worldwide for more than 25 years, Simulations Plus is a leading provider in the biosimulation market providing software and consulting services supporting drug discovery, development, research, and regulatory submissions. We offer solutions that bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on LinkedIn | Twitter | YouTube.
Environmental, Social, and Governance (ESG)
We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our ESG Report.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports and filed with the U.S. Securities and Exchange Commission.